Sealantium Medical is proud to announce a key milestone in its collaboration with Belgian CDMO SimAbs, with the signing of a Quality Agreement that marks the successful completion of the first phase of the manufacturing preparation for sFilm-FS™. This agreement lays the foundation for GMP manufacturing and supports the preparation for large-scale clinical and commercial readiness.
SimAbs brings deep expertise in biologics and GMP-compliant manufacturing, with a strong track record in quality and regulatory alignment. Their capabilities make them an ideal partner as Sealantium advances toward Phase III clinical studies and positions sFilm-FS™ for broader market entry.
sFilm-FS™ is Sealantium’s fully synthetic hemostatic and tissue sealing film, specifically designed to meet the demands of both open and minimally invasive surgeries. Its flexible, ready-to-use format offers fast, reliable bleeding control and overcomes key limitations of existing fibrin-based solutions—particularly during high-risk or technically complex procedures.
This milestone not only reflects Sealantium’s executional progress but also reinforces its commitment to delivering safer, more effective tools for surgical bleeding control and fluid management.
As global demand for advanced hemostatic solutions continues to grow, Sealantium remains focused on building strong, strategic partnerships that accelerate innovation and bring clinical impact to patients worldwide.
